GlassScriptPhysician profile
Anais Barrera
NPI 1821723891
$5,149.49
in general payments reported to CMS, 2019-2025
37 companies · $4,114 in 2025
The $4,114 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $354 · 2024: $681 · 2025: $4,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,149.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.37 | 2024-2025 | |
| Madrigal Pharmaceuticals | $485.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $377.71 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $346.94 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $306.22 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Antares Pharma, INC. | $261.97 | 2024-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $248.21 | 2024-2025 | |
| Pfizer INC. | $188.84 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $188.26 | 2025 | Zenpep |
| Dexcom, INC. | $185.21 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.65 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $170.06 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $148.84 | 2025 | Voquezna |
| Galderma Laboratories, L.P. | $124.91 | 2023 | |
| Beta Bionics, INC. | $111.72 | 2024 | Ilet Bionic Pancreas |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $104.70 | 2023 | Xeomin |
| Lundbeck LLC | $99.05 | 2024-2025 | Rexulti, Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $95.31 | 2024-2025 | |
| Corcept Therapeutics | $81.21 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $78.33 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $69.47 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.38 | 2025 | Caplyta |
| Astellas Pharma US INC | $48.44 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $47.93 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cequr Corporation | $45.93 | 2025 | Cequr Simplicity |
| Medtronic, INC. | $45.51 | 2025 | Minimed 780g |
| Verity Pharmaceuticals INC. | $44.58 | 2025 | Tlando |
| Abbott Laboratories | $37.34 | 2025 | Freestyle Libre 3, Proclaim |
| Sumitomo Pharma America, INC. | $25.14 | 2025 | Gemtesa |
| Organon LLC | $22.78 | 2025 | Nexplanon |
| Mannkind Corporation | $18.27 | 2025 | |
| Insulet Corporation | $17.43 | 2025 | Omnipod |
| Nalu Medical, INC. | $16.37 | 2025 | Nalu Neurostimulation System |
| Tempus Ai, INC | $16.18 | 2024 | Tempus Pixel |
| Tolmar, INC. | $15.68 | 2024 | |
| Ibsa Pharma INC. | $15.16 | 2024 | Licart, Tirosint |
| Currax Pharmaceuticals LLC | $13.92 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anais Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.